An Open-Label Study of OROS-Methylphenidate for Neuropsychological Changes in Children and Adolescents with Attention-Deficit Hyperactivity Disorder
![]() |
Kook, So-Dahm
(Department of Psychiatry, Myongji Hospital)
Kim, Joo-Young (Yonsei Junior Clinic) Cheon, Keun-Ah (Department of Child and Adolescent Psychiatry, College of Medicine, Yonsei University) Jhung, Kyungun (Department of Psychiatry, Konyang University College of Medicine) Song, Dong-Ho (Department of Child and Adolescent Psychiatry, College of Medicine, Yonsei University) |
1 | Connor DF, Ford JD. Comorbid symptom severity in attention-deficit/ hyperactivity disorder: a clinical study. J Clin Psychiatry 2012; 73:711-717. DOI ScienceOn |
2 | Lambert NM, Sandoval J. The prevalence of learning disabilities in a sample of children considered hyperactive. J Abnorm Child Psychol 1980;8:33-50. DOI |
3 | Fischer M, Barkley RA, Smallish L, Fletcher K. Young adult followup of hyperactive children: self-reported psychiatric disorders, comorbidity, and the role of childhood conduct problems and teen CD. J Abnorm Child Psychol 2002;30:463-475. DOI ScienceOn |
4 | Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;57:1313-1323. DOI ScienceOn |
5 | Noland JS, Singer LT, Short EJ, Minnes S, Arendt RE, Kirchner HL, et al. Prenatal drug exposure and selective attention in preschoolers. Neurotoxicol Teratol 2005;27:429-438. DOI ScienceOn |
6 | Indredavik MS, Vik T, Heyerdahl S, Kulseng S, Fayers P, Brubakk AM. Psychiatric symptoms and disorders in adolescents with low birth weight. Arch Dis Child Fetal Neonatal Ed 2004;89:F445-F450. DOI ScienceOn |
7 | Shaywitz SE, Cohen DJ, Shaywitz BA. The biochemical basis of minimal brain dysfunction. J Pediatr 1978;92:179-187. DOI |
8 | Schneider JS, Sun ZQ, Roeltgen DP. Effects of dopamine agonists on delayed response performance in chronic low-dose MPTP-treated monkeys. Pharmacol Biochem Behav 1994;48:235-240. DOI ScienceOn |
9 | Castellanos FX, Tannock R. Neuroscience of attention-deficit/hyperactivity disorder: the search for endophenotypes. Nat Rev Neurosci 2002;3:617-628. DOI ScienceOn |
10 | Castellanos FX, Lee PP, Sharp W, Jeffries NO, Greenstein DK, Clasen LS, et al. Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder. JAMA 2002;288:1740-1748. DOI ScienceOn |
11 | Barkley RA. Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol Bull 1997;121:65-94. DOI ScienceOn |
12 | Pennington BF, Ozonoff S. Executive functions and developmental psychopathology. J Child Psychol Psychiatry 1996;37:51-87. DOI ScienceOn |
13 | Schachar R, Mota VL, Logan GD, Tannock R, Klim P. Confirmation of an inhibitory control deficit in attention-deficit/hyperactivity disorder. J Abnorm Child Psychol 2000;28:227-235. DOI ScienceOn |
14 | Biederman J, Monuteaux MC, Doyle AE, Seidman LJ, Wilens TE, Ferrero F, et al. Impact of executive function deficits and attentiondeficit/ hyperactivity disorder (ADHD) on academic outcomes in children. J Consult Clin Psychol 2004;72:757-766. DOI ScienceOn |
15 | Sonuga-Barke EJ, Sergeant JA, Nigg J, Willcutt E. Executive dysfunction and delay aversion in attention deficit hyperactivity disorder: nosologic and diagnostic implications. Child Adolesc Psychiatr Clin N Am 2008;17:367-384, ix. DOI ScienceOn |
16 | Park SM, Shin MS. Comparison of executive function in children with ADHD and anxiety disorder. J Kor Acad Child Adolesc Psychiatry 2010;21:147-152. 과학기술학회마을 DOI ScienceOn |
17 | Vance AL, Maruff P, Barnett R. Attention deficit hyperactivity disorder, combined type: better executive function performance with longer-term psychostimulant medication. Aust N Z J Psychiatry 2003;37:570-576. DOI ScienceOn |
18 | Yoo HY, Kim B, Joung YS, Bahn GH, Song DH, Ahn DH, et al. An open-label study of the improvements in clinical symptoms and neurocognitive functions in Korean children and adolescents with attention-deficit hyperactivity disorder after treatment with metadate CD. J Kor Acad Child Adolesc Psychiatry 2011;22:253-261. 과학기술학회마을 DOI ScienceOn |
19 | Snyder AM, Maruff P, Pietrzak RH, Cromer JR, Snyder PJ. Effect of treatment with stimulant medication on nonverbal executive function and visuomotor speed in children with attention deficit/hyperactivity disorder (ADHD). Child Neuropsychol 2008;14:211-226. DOI ScienceOn |
20 | Aron AR, Dowson JH, Sahakian BJ, Robbins TW. Methylphenidate improves response inhibition in adults with attention-deficit/ hyperactivity disorder. Biol Psychiatry 2003;54:1465-1468. DOI ScienceOn |
21 | Kim Y, Shin MS, Kim JW, Yoo HJ, Cho SC, Kim BN. Neurocognitive effects of switching from methylphenidate-IR to OROS-methylphenidate in children with ADHD. Hum Psychopharmacol 2009; 24:95-102. DOI ScienceOn |
22 | Klein C, Wendling K, Huettner P, Ruder H, Peper M. Intra-subject variability in attention-deficit hyperactivity disorder. Biol Psychiatry 2006;60:1088-1097. DOI ScienceOn |
23 | Golden CJ. Identification of brain disorders by the Stroop Color and Word Test. J Clin Psychol 1976;32:654-658. DOI |
24 | Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T, et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2006;59:829-835. DOI ScienceOn |
25 | Swanson J, Gupta S, Lam A, Shoulson I, Lerner M, Modi N, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proofof- concept and proof-of-product studies. Arch Gen Psychiatry 2003; 60:204-211. DOI ScienceOn |
26 | DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. A DHD Rating Scale-IV: C hecklists, Norms a nd Clinical I nterpretations. New York, NY: Guilford Press; 1998. |
27 | Kuczenski R, Segal DS. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem 1997;68:2032-2037. |
28 | Kim YS, Cheon KA, Kim BN, Chang SA, Yoo HJ, Kim JW, et al. The reliability and validity of Kiddie-Schedule for Affective Disorders and Schizophrenia-Present and Lifetime Version- Korean version (K-SADS-PL-K). Yonsei Med J 2004;45:81-89. 과학기술학회마을 DOI ScienceOn |
29 | Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville: US Department of Heath, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration; 1976. |
30 | Goyette CH, Conners CK, Ulrich RF. Normative data on revised Conners Parent and Teacher Rating Scales. J Abnorm Child Psychol 1978;6:221-236. DOI ScienceOn |
31 | Shim MS, Cho SZ, Chun SY, Hong KE. A study of the development and standardization of ADHD diagnostic system. J Korean Acad Child Adolesc Psychiatry 2000;11:91-99. 과학기술학회마을 |
32 | Stroop JR. Studies of interference in serial verbal reactions. Exp Psychol 1935;18:643-662. DOI |
33 | Wilens TE, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, et al. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 2006;160:82-90. DOI ScienceOn |
34 | Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Can J Clin Pharmacol 2006;13:e50-e62. |
35 | Miyake A, Friedman NP, Emerson MJ, Witzki AH, Howerter A, Wager TD. The unity and diversity of executive functions and their contributions to complex "Frontal Lobe" tasks: a latent variable analysis. Cogn Psychol 2000;41:49-100. DOI ScienceOn |
36 | Perwien A, Hall J, Swensen A, Swindle R. Stimulant treatment patterns and compliance in children and adults with newly treated attention- deficit/hyperactivity disorder. J Manag Care Pharm 2004; 10:122-129. |
![]() |